BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers
BIOSTEM TECHNOLOGIES NEW (BSEM)
NASDAQ:AMEX Investor Relations:
otcmarkets.com/stock/bsem/news/biostem-technologies-inc--announces-a-pre-clinical-study-of-bsem17-115-at-university-of-miami?id=177750&b=y
Company Research
Source: GlobeNewswire
Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth The study will be conducted in 60 patients at 10 sites across the U.S. and the first patients have begun treatment POMPANO BEACH, Fla., Oct. 02, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces the initiation of the BR-AC-DFU-101 (BioREtain - Amnion Chorion - Diabetic Foot Ulcers) clinical trial to evaluate BR-AC (BioREtain - Amnion Chorion) against the standard of care for patients suffering from non-healing diabetic foot ulcers (DFUs). Study Overview and Design:The BR-AC-DFU-101 study will examine a patient population with a DFU (diabetic foot ulcer) that has adequate perfusion without clinical signs and symptoms of infection. The trial will enroll 6
Show less
Read more
Impact Snapshot
Event Time:
BSEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BSEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BSEM alerts
High impacting BIOSTEM TECHNOLOGIES NEW news events
Weekly update
A roundup of the hottest topics
BSEM
News
- BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare GlobalGlobeNewswire
- BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 MillionGlobeNewswire
- BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) RegionsGlobeNewswire
- BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024GlobeNewswire
- BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care TreatmentGlobeNewswire